Profile
Lyda M.
Osorio is currently the Head-Pharmacology at IMED AB.
Prior to this, she worked as a Principal at Karolinska Institutet.
Lyda M. Osorio active positions
Companies | Position | Start |
---|---|---|
IMED AB
IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Corporate Officer/Principal | 2009-11-25 |
Former positions of Lyda M. Osorio
Companies | Position | End |
---|---|---|
Karolinska Institutet | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
IMED AB
IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Retail Trade |
- Stock Market
- Insiders
- Lyda M. Osorio